Open Access<p><em>Orexin/Hypocretin Type 2 Receptor</em> (<em>HCRTR2</em>) Gene as a Candidate Gene in Sertraline-Associated Insomnia in Depressed Patients</p>
Author(s) -
Negar Firouzabadi,
Niloofar Navabzadeh,
Ebrahim Moghimi-Sarani,
Maral Haghnegahdar
Publication year - 2020
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s250141
Subject(s) - medicine , insomnia , sertraline , major depressive disorder , orexin , odds ratio , gastroenterology , psychiatry , endocrinology , antidepressant , receptor , amygdala , neuropeptide , hippocampus
Selective serotonin reuptake inhibitors (SSRIs) are considered as rst-line drugs for treating depressive disorders. Among the adverse effects reported with sertraline is sleep disturbances; however, the etiology lying beneath is obscure. Orexin, the most recently discovered neurotransmitter, is involved in the sleep cycle. It exerts its physiological actions through orexin or hypocretin type 1 and 2 receptors (HCRTR1 and HCRTR2). Dysfunction of the orexin system contributes to various psychiatric, neurologic and neuropsychiatric disorders. Thus, our study aimed to assess the possible association of genetic variation of HCRTR2 G1246A with hypersomnia reported with sertraline in a group of major depressive disorder (MDD) patients.